Naloxone is a medicine approved for treatment of opioid overdose in 1971 but only available as an injection. Recognizing the need for a means of delivering naloxone to overdose victims as quickly and effectively as an injection, Opiant (then Lightlake) collaborated with the National Institute on Drug Abuse (part of the National Institutes of Health) to develop a concentrated formulation of naloxone that could be administered intranasally, going from concept to FDA approval in just 3 years.
NARCAN® Nasal Spray delivers a life-saving dose of the opioid antagonist naloxone with the effective speed of an injection. Packaged as a single use nasal spray; it can be used with little or no prior training. This product was licensed to Adapt Pharma (now a division of Emergent BioSolutions) in 2014, and since its approval, has saved the lives of thousands of overdose victims.
|Preclinical||Phase I||Phase II||Phase III||NDA||FDA Approval|